文献速递细菌感染、耐药与抗菌药物医院感染防控

口服抗生素联合粪菌移植清除多重耐药肠杆菌定植的随机临床试验

A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial.
PubMed 文献 · Clin Microbiol Infect · 2019-01-04

意向性分析显示干预组41%(9/22)在随机后35-48天培养阴性,对照组29%(5/17)阴性,OR 1.7(95%CI 0.4-6.4),差异无统计学意义,可能因试验提前终止。

要点

  • 5天口服多粘菌素E+新霉素后粪菌移植,在35-48天时ESBL-E/CPE定植清除率41% vs 29%,差异无统计学意义。
  • 研究药物总体耐受良好,但3例因腹泻提前停用抗生素(均接受了粪菌移植)。
  • 该策略较对照仅轻微降低定植率,需进一步临床研究验证。

核心结论

  • 非吸收性抗生素后粪菌移植较对照轻微降低ESBL-E/CPE肠道定植,但差异无统计学意义,可能因试验提前终止。

研究设计与样本

  • 随机、开放标签、优势试验,在日内瓦、巴黎、乌得勒支、特拉维夫四个三级中心开展。
  • 非免疫抑制成人按1:1随机分为无干预对照组或5天口服抗生素(多粘菌素E硫酸盐2×10^6 IU 每日4次;新霉素硫酸盐500 mg 每日4次)后接受来自无关健康供者的冻存粪菌移植。

主要发现

  • 意向性分析中,干预组9/22(41%)在随机后35-48天(V4)粪便培养ESBL-E/CPE阴性(1例未接受干预按阳性插补),对照组5/17(29%)阴性(1例失访按阴性插补)。
  • 定植清除成功的OR为1.7(95%CI 0.4-6.4)。
  • 研究药物总体耐受良好,但干预组3例因腹泻提前停用研究抗生素(均接受了粪菌移植)。

临床怎么用

  • 对于ESBL-E/CPE肠道定植患者,5天口服多粘菌素E联合新霉素后粪菌移植的策略在当前证据下不推荐作为常规去定植方案。
  • 临床决策时应告知患者该策略清除率有限且差异未达统计学意义,并注意腹泻可能导致抗生素提前停用。

局限性

  • 开放标签设计可能引入偏倚。
  • 意向性分析中对未接受干预和失访病例采用了插补假设。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Intestinal carriage with extended spectrum β-lactamase Enterobacteriaceae (ESBL-E) and carbapenemase-producing Enterobacteriaceae (CPE) can persist for months. We aimed to evaluate whether oral antibiotics followed by faecal microbiota transplantation (FMT) can eradicate intestinal carriage with ESBL-E/CPE. METHODS: Randomized, open-label, superiority trial in four tertiary-care centres (Geneva (G), Paris (P), Utrecht (U), Tel Aviv (T)). Non-immunocompromised adult patients were randomized 1: 1 to either no intervention (control) or a 5-day course of oral antibiotics (colistin sulphate 2 × 106 IU 4×/day; neomycin sulphate 500 mg 4×/day) followed by frozen FMT obtained from unrelated healthy donors. The primary outcome was detectable intestinal carriage of ESBL-E/CPE by stool culture 35-48 days after randomization (V4). ClinicalTrials.govNCT02472600. The trial was funded by the European Commission (FP7). RESULTS: Thirty-nine patients (G = 14; P = 16; U = 7; T = 2) colonized by ESBL-E (n = 36) and/or CPE (n = 11) were enrolled between February 2016 and June 2017. In the intention-to-treat analysis 9/22 (41%) patients assigned to the intervention arm were negative for ESBL-E/CPE at V4 (1/22 not receiving the intervention imputed as positive) whereas in the control arm 5/17 (29%) patients were negative (one lost to follow up imputed as negative) resulting in an OR for decolonization success of 1.7 (95% CI 0.4-6.4). Study drugs were well tolerated overall but three patients in the intervention group prematurely stopped the study antibiotics because of diarrhoea (all received FMT). CONCLUSIONS: Non-absorbable antibiotics followed by FMT slightly decreased ESBL-E/CPE carriage compared with controls; this difference was not statistically significant, potentially due to early trial termination. Further clinical investigations seem warranted.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Huttner BD, de Lastours V, Wassenberg M, et al. A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial. Clin Microbiol Infect. 2019. PMID: 30616014. doi:10.1016/j.cmi.2018.12.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。